The 26 analysts offering 12-month price forecasts for Teladoc Health Inc have a median target of 95.00, with a high estimate of 161.00 and a low estimate of 60.00. The median estimate represents a +38.06% increase from the last price of 68.81.
Similarly, Will Pacb stock go up?
Stock Price Forecast
The 6 analysts offering 12-month price forecasts for Pacific Biosciences of California Inc have a median target of 20.00, with a high estimate of 40.00 and a low estimate of 13.00. The median estimate represents a +146.15% increase from the last price of 8.13.
Who are teladoc competitors? Teladoc Health’s top competitors include naviHealth, Lash Group, Amwell, 98point6, MDLIVE, Providence Service Corporation and Sharecare. Teladoc Health is a telehealth company that uses telephone and video conferencing technology to provide on-demand remote medical care via mobile devices, the internet, and video.
Thereof, Is Tdoc buy or sell?
The Historical Cash Flow Growth is the longer-term (3-5 year annualized) growth rate of the cash flow change.
…
Momentum Scorecard. More Info.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.93% |
| 2 | Buy | 18.44% |
| 3 | Hold | 9.99% |
| 4 | Sell | 5.61% |
Why is Tdoc stock down?
The stock price of Teladoc (NASDAQ:TDOC), a telemedicine and virtual healthcare company, has seen a fall of 20% over the last month, while it is down more than 70% over the last one year. The market is trying to look beyond Covid-19, as therapeutic options for Covid-19 improve and as the virus potentially gets milder.
Should I buy PACB?
The financial health and growth prospects of PACB, demonstrate its potential to underperform the market. It currently has a Growth Score of F. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of A.
Is PACB a buy now?
Out of 2 analysts, 1 (50%) are recommending PACB as a Strong Buy, 0 (0%) are recommending PACB as a Buy, 1 (50%) are recommending PACB as a Hold, 0 (0%) are recommending PACB as a Sell, and 0 (0%) are recommending PACB as a Strong Sell. What is PACB’s earnings growth forecast for 2022-2024?
Should I buy BNGO?
Based on his analysis, DeGeeter rates BNGO stock as “outperform” with a $14 value. Other analysts are also bullish on the company. Those tracked by the Wall Street Journal have BNGO rated as a consensus “buy” with an average $12 price target.
How does Teladoc make money?
How does Teladoc Make Money? Teladoc’s major revenue source is from the subscription-based model. Patients pay annual or monthly fees for consultation. The subscription-based plan starts from $49, they also sell services to clients on behalf of their employees.
How many customers does Teladoc have?
It trades on the NYSE and in 2019 was active in 130 countries and served around 40 million members in 2021.
Who is Teladoc biggest competitor?
1. Amwell. Amwell (NYSE: AMWL) formerly known as American Well, is a telemedicine company founded in 2006 and went public in 2020. It is currently the biggest competitor to Teladoc in the telehealth space and has experienced significant growth in recent times.
Is teladoc undervalued?
Is Teladoc Stock Undervalued? TDOC is not profitable yet, thus we can’t value the company on a price-to-earnings basis. We can look at other metrics to gauge whether shares are expensive, however.
Will teladoc rebound?
They’re trading at little more than four times sales. This is their lowest by that measure since 2016. It’s impossible to predict when Teladoc will rebound.
Will teladoc stock recover?
Teladoc stock is set for a big comeback, says Goldman Sachs.
Teladoc (ticker: TDOC) stock was battered in 2021. Though memberships boomed as the pandemic unfolded in 2020, sending the stock up nearly 139% that year, such gains created a high bar that Teladoc struggled to clear the following year.
Is Teladoc going to recover?
Teladoc stock is set for a big comeback, says Goldman Sachs.
Teladoc (ticker: TDOC) stock was battered in 2021. Though memberships boomed as the pandemic unfolded in 2020, sending the stock up nearly 139% that year, such gains created a high bar that Teladoc struggled to clear the following year.
Is Teladoc undervalued?
Is Teladoc Stock Undervalued? TDOC is not profitable yet, thus we can’t value the company on a price-to-earnings basis. We can look at other metrics to gauge whether shares are expensive, however.
Is Teladoc overvalued?
Given these points, I continue to recommend selling TDOC stock. Although the company does have some positive catalysts, including its partnership with CVS (NYSE:CVS) and its strong brand name, the shares remain tremendously overvalued, despite their recent pullback.
Is PACB a good company?
GET POWR RATINGS…
Growth is the dimension where PACB ranks best; there it ranks ahead of 55.21% of US stocks. The strongest trend for PACB is in Momentum, which has been heading down over the past 179 days. PACB’s current lowest rank is in the Stability metric (where it is better than 9.22% of US stocks).
What does PACB company do?
(aka PacBio) is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation.
Who owns Pacific Biosciences?
Institutional investors purchased a net $27.7 million shares of PACB during the quarter ended June 2019 and now own 97.49% of the total shares outstanding.
…
Top 10 Owners of Pacific Biosciences of California Inc.
| Stockholder | The Vanguard Group, Inc. |
|---|---|
| Stake | 8.78% |
| Shares owned | 19,417,297 |
| Total value ($) | 176,697,403 |
Join TheMoney.co community and don’t forget to share this post !